Clinical Cancer Research The Science of Cancer Health Disparities Stand Up to Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 5967-5976, October 1, 2008. doi: 10.1158/1078-0432.CCR-07-4535
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Chau, C. H.
Right arrow Articles by Figg, W. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chau, C. H.
Right arrow Articles by Figg, W. D.
Related Collections
Right arrow Clinical Research
Right arrow Clinical Research: Response Markers and Mechanisms

CCR Focus

Validation of Analytic Methods for Biomarkers Used in Drug Development

Cindy H. Chau1, Olivier Rixe1, Howard McLeod2 and William D. Figg1

Authors' Affiliations: 1 Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland and 2 Institute for Pharmaco-genomics and Individualized Therapy, University of North Carolina, Chapel Hill, North Carolina

Requests for reprints: Howard McLeod, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Campus Box 7360, 3203 Kerr Hall, Chapel Hill, NC 27599-7360. Phone: 919-966-0512; E-mail: hmcleod{at}unc.edu or William D. Figg, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Building 10/Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892. Phone: 301-402-3623; Fax: 301-402-8606; E-mail: wdfigg{at}helix.nih.gov.

Abstract

The role of biomarkers in drug discovery and development has gained precedence over the years. As biomarkers become integrated into drug development and clinical trials, quality assurance and, in particular, assay validation become essential with the need to establish standardized guidelines for analytic methods used in biomarker measurements. New biomarkers can revolutionize both the development and use of therapeutics but are contingent on the establishment of a concrete validation process that addresses technology integration and method validation as well as regulatory pathways for efficient biomarker development. This perspective focuses on the general principles of the biomarker validation process with an emphasis on assay validation and the collaborative efforts undertaken by various sectors to promote the standardization of this procedure for efficient biomarker development.




This article has been cited by other articles:


Home page
CRO ContentHome page
G. C. Prendergast
Clinical Research: Effective Integration of Laboratory Advances Into Clinical Trials
Cancer Reviews Online Content, January 1, 2008; 2008(11): 21 - 21.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.